These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9026943)

  • 41. Clinical and biological characteristics of familial benign prostatic hyperplasia.
    Sanda MG; Doehring CB; Binkowitz B; Beaty TH; Partin AW; Hale E; Stoner E; Walsh PC
    J Urol; 1997 Mar; 157(3):876-9. PubMed ID: 9072590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 1992; 147(1-2):125-35; discussion 135-7. PubMed ID: 1384903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical studies on morphological changes in the prostate in patients with benign prostatic hypertrophy after antiandrogen therapy--by means of transrectal ultrasonotomography].
    Suzuki K; Ichinose Y; Hashimoto K; Matsumoto K; Suzuki T; Imai K; Yamanaka H
    Hinyokika Kiyo; 1990 May; 36(5):557-60. PubMed ID: 1698012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The anti-androgen flutamide in the treatment of prostatic hyperplasia].
    Romics I; Bach D
    Orv Hetil; 1992 Nov; 133(47):3023-5. PubMed ID: 1279497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Evaluation of the clinical effect of lisuride hydrogen maleate (SH-1072) on benign prostatic hypertrophy: on the clinical results and mechanism of action].
    Okada K; Yamauchi T; Oishi K; Hashimura T; Kawamura J; Yoshida O
    Hinyokika Kiyo; 1985 May; 31(5):885-93. PubMed ID: 2413748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacotherapy of benign prostatic hyperplasia: inhibitor of 5 alpha-reductase.
    Polat O; Ozbey I; Gül O; Demirel A; Bayraktar Y
    Int Urol Nephrol; 1997; 29(3):323-30. PubMed ID: 9285305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Antiandrogen therapy of benign prostatic hypertrophy: clinical effects of allylestrenol evaluated by transrectal ultrasonographic measurement].
    Tsuji Y; Ariyoshi A; Nakamura H; Michinaga S; Tomita Y; Ohmori A; Tahara H; Yamashita Y; Fujisawa Y; Kajiwara I
    Hinyokika Kiyo; 1992 Aug; 38(8):961-6. PubMed ID: 1384295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Benign prostatic hyperplasia: CPG, PSA and 5-alpha-reductase inhibitors].
    Comite Scientifique d'Organisation
    Ann Urol (Paris); 2004 Dec; 38 Suppl 2():S17-8. PubMed ID: 15651485
    [No Abstract]   [Full Text] [Related]  

  • 49. [Clinical effects of allylestrenol on prostatic hypertrophy].
    Kohri K; Kurita T; Iguchi M; Kataoka K
    Hinyokika Kiyo; 1986 Mar; 32(3):486-92. PubMed ID: 2425611
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update.
    Niżański W; Levy X; Ochota M; Pasikowska J
    Reprod Domest Anim; 2014 Jun; 49 Suppl 2():8-15. PubMed ID: 24947855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical effect of allylestrenol on benign prostatic hypertrophy].
    Tajima A; Aso Y; Ushiyama T; Hata M; Kambayashi T; Ohmi Y; Masuda H; Nakahara M; Kitagawa M; Suzuki A
    Hinyokika Kiyo; 1986 Mar; 32(3):477-85. PubMed ID: 2425610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Prostagut forte treatment of patients with prostatic adenoma with comorbid chronic prostatitis].
    Avdoshin VP; Pul'bere SA
    Urologiia; 2012; (2):44, 46-7. PubMed ID: 22876633
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia.
    Weisser H; Tunn S; Behnke B; Krieg M
    Prostate; 1996 May; 28(5):300-6. PubMed ID: 8610056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Conservative treatment of benign prostatic hypertrophy: reevaluation of the effect of eviprostat by subjective symptoms and uroflowmetry].
    Matsuura T; Wakabayashi A; Kaneko S; Kurita T
    Hinyokika Kiyo; 1986 Jun; 32(6):903-6. PubMed ID: 2429533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The conservative treatment of early-stage benign prostatic hypertrophy].
    Kumanov Kh; Stoianova V; Lilov A; Kaloianov D
    Khirurgiia (Sofiia); 1993; 46(5):5-6. PubMed ID: 7527092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters.
    Bosch RJ; Griffiths DJ; Blom JH; Schroeder FH
    J Urol; 1989 Jan; 141(1):68-72. PubMed ID: 2462067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Approach to benign hypertrophy of the prostate in primary health care].
    Bentué Ferrer C; Córdoba García R
    Aten Primaria; 1995 Apr; 15(7):461-4. PubMed ID: 7539299
    [No Abstract]   [Full Text] [Related]  

  • 58. The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. The Zanoterone Study Group.
    Berger BM; Naadimuthu A; Boddy A; Fisher HA; McConnell JD; Milam D; Mobley D; Rajfer J
    J Urol; 1995 Sep; 154(3):1060-4. PubMed ID: 7543598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The preoperative anti-inflammatory and postoperative therapy of patients with calculous pyelonephritis and prostatic adenoma with chronic prostatitis under outpatient polyclinic conditions].
    Shabad AL; Minakov NK; Mkrtchan GG; Zabirov KI
    Urol Nefrol (Mosk); 1994; (5):24-7. PubMed ID: 7532881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Evaluation of prazosin in the treatment of benign hypertrophy of the prostate. A case-control study].
    Adriazola Semino M; García Cobo E; De la Calle Muñoz I; Tejeda Bañez E; Romero F
    Actas Urol Esp; 1993 Jul; 17(7):402-4. PubMed ID: 7690177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.